Published on 3 May 2021 on Benzinga via Yahoo Finance
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S. government's decision to support for taking vaccine technology and intellectual property off patent.
ChemoCentryx, Inc. (NASDAQ: CCXI) shares went from $48.32 to $10.46 over the week, a pullback of over 78% on the back of a negative Adcom verdict.